Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 13,063 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Relapsed or Refractory Follicular Lymphoma
Interventions: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more

Conditions: Lymphoma, Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63); Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 63
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more

Conditions: Brain and Central Nervous System Tumors
Interventions: adjuvant therapy, iodine I 125; Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Anterior Cruciate Ligament Injuries, Post-Traumatic Osteoarthritis of Knee, Bone Marrow Aspirate Concentrate, ACL Injury
Interventions: Concentrated Bone Marrow Aspirate Injection, Sham Incision, Revision Anterior Cruciate Ligament Reconstruction; Biological · Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Cervical Dystonia
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Any FDA Approved Antidepressant; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hallux Limitus
Interventions: Metatarsophalangeal Extension Dynasplint System, Standard of Care; Device · Other
Lead sponsor: Dynasplint Systems, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Jonesboro, Georgia • Marietta, Georgia

Conditions: Major Depressive Disorder
Interventions: 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Lafayette, California • Lemon Grove, California • Oceanside, California + 20 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Thrombocytopenia
Interventions: Avatrombopag; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more

Conditions: Menthol Cigarettes, Smoking Behavior, Cigarette Use
Interventions: Message Exposure via Discrete Choice Experiment; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Santa Barbara, California • Atlanta, Georgia

Conditions: Spinal Cord Stimulation, Deep Brain Stimulation, Drug Infusion (Implantable Pumps), Sacral Neuromodulation
Interventions: Various; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: Not listed
Enrollment: 10,981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 43
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Aliso Viejo, California + 40 more

Conditions: Glioblastoma Multiforme of Brain
Interventions: TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide; Biological · Procedure · Radiation + 1 more
Lead sponsor: TVAX Biomedical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more

Conditions: Vulvovaginal Atrophy
Interventions: WC3011 Estradiol Vaginal Cream, Vehicle; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more

Conditions: Ovarian Cancer
Interventions: avelumab, PLD; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 87
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more

Conditions: Colorectal Cancer
Interventions: bevacizumab, capecitabine, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: Prologue Research International; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 52
States / cities: Birmingham, Alabama • Tucson, Arizona • Greenbrae, California + 47 more

Conditions: Endometrial Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more

Conditions: Breast Screening
Interventions: Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 45 Years to 74 Years · Female only
Enrollment: 108,508 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 133
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more

Conditions: Multiple Sclerosis, Relapsing
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Plaque Psoriasis, Scalp Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 79
States / cities: Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution; Biological · Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more

Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Edodekin alfa, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 27
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ofatumumab approved dose, Ofatumumab new dose; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more

Search by objective public record fields.

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Brachytherapy in Treating Patients With Recurrent Malignant Glioma

Concentrated Bone Marrow Aspirate in Revision ACL Reconstruction

Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Effects of Treatment on Decision-making in Major Depression

Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

DoubleTake: Effect of Message Exposure Via a Discrete Choice Experiment With Eye-Tracking on Quit Attempts Among Adults Who Smoke Menthol Cigarettes

Implantable Systems Performance Registry

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

Phase 2/3 Study of IGSC, 20% in PIDD

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes